Pinnacle Wealth Management Advisory Group LLC reduced its position in Bristol-Myers Squibb Co (NYSE:BMY) by 6.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,881 shares of the biopharmaceutical company’s stock after selling 1,435 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Bristol-Myers Squibb were worth $1,234,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Raymond James Financial Services Advisors Inc. lifted its position in Bristol-Myers Squibb by 2.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock worth $22,827,000 after acquiring an additional 10,456 shares in the last quarter. SFE Investment Counsel lifted its position in Bristol-Myers Squibb by 8.6% during the 3rd quarter. SFE Investment Counsel now owns 16,375 shares of the biopharmaceutical company’s stock worth $1,017,000 after acquiring an additional 1,290 shares in the last quarter. Toronto Dominion Bank lifted its position in Bristol-Myers Squibb by 19.1% during the 2nd quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock worth $58,813,000 after acquiring an additional 170,360 shares in the last quarter. Aperio Group LLC lifted its position in Bristol-Myers Squibb by 9.9% during the 3rd quarter. Aperio Group LLC now owns 928,404 shares of the biopharmaceutical company’s stock worth $57,635,000 after acquiring an additional 83,708 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock worth $6,830,000 after acquiring an additional 2,323 shares in the last quarter. 72.90% of the stock is currently owned by institutional investors and hedge funds.

BMY stock opened at $53.52 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a 52-week low of $46.94 and a 52-week high of $70.05. The company has a market cap of $87.29 billion, a price-to-earnings ratio of 17.78, a price-to-earnings-growth ratio of 1.49 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, equities analysts forecast that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were issued a dividend of $0.40 per share. The ex-dividend date was Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 2.99%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

Several equities analysts recently commented on BMY shares. Barclays boosted their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Friday, October 12th. Morgan Stanley reduced their price target on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, November 6th. Credit Suisse Group set a $61.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, October 14th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Friday, October 5th. Finally, ValuEngine lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $61.84.

COPYRIGHT VIOLATION WARNING: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/11/21/bristol-myers-squibb-co-bmy-shares-sold-by-pinnacle-wealth-management-advisory-group-llc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Read More: Outstanding Shares

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.